Physician profile
Michael David Cecil
NPI 1396254314
$166.60
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $167.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $38.69 | 2021 | |
| Abbott Laboratories | $36.58 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.33 | 2021 | |
| Lundbeck LLC | $22.74 | 2021 | |
| Neurocrine Biosciences, INC. | $15.16 | 2021 | |
| Orthofix Medical, INC. | $14.78 | 2021 | |
| Abbvie INC. | $13.32 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cecil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.